Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

9.000 USD -0.100 (-1.10%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Inovio Pharma

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Inovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 second quarter financial results on Tuesday, August 8, 2017 at 4:30... 
From GlobeNewswire News Releases
Inovio Announces Pricing of Public Offering of Common Stock
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, offered at a price to the public of $6.00 per share.... 
From GlobeNewswire News Releases
Inovio Announces Proposed Public Offering of Common Stock
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering. Inovio expects to grant the... 
From GlobeNewswire News Releases
Inovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
Inovio dMAb® product induces complete protection against lethal challenge with influenza A & B viruses in published preclinical study 
From GlobeNewswire News Releases
Inovio Announces Leadership Appointments
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice... 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled “Platform Technologies: The Key to Responding to Emerging... 
From GlobeNewswire News Releases
Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Inovio is developing this... 
From GlobeNewswire News Releases
Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
FDA removes clinical hold on phase 3; Inovio to immediately begin recruiting subjects 
From GlobeNewswire News Releases
Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
Zika DNA vaccine may protect against sexual transmission 
From GlobeNewswire News Releases
Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor
Phase 1b/2 clinical trial to evaluate combination of Inovio’s T cell immunotherapy INO-5401 and Genentech’s PD-L1 checkpoint inhibitor atezolizumab 
From GlobeNewswire News Releases
Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human study 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2017. 
From GlobeNewswire News Releases
Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
Phase 1b/2a study combines MedImmune’s MEDI0457 (INO-3112), a DNA-based immunotherapy targeting HPV-associated cancer, and durvalumab, an immune checkpoint (PD-L1) inhibitor 
From GlobeNewswire News Releases
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer 
From PR Newswire
Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Phase 1b/2a clinical trial will combine Regeneron’s PD-1 inhibitor REGN2810 and Inovio’s T cell activator INO-5401 and immune activator INO-9012 in brain cancer 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference May 16-18th, 2017 in Las Vegas, NV. Dr. J. Joseph Kim,... 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Report First Quarter 2017 Financial Results May 10, 2017
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 first quarter financial results on Wednesday, May 10, 2017 at 4:30 p.m.... 
From GlobeNewswire News Releases
Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced a phase 2 trial to evaluate the efficacy of VGX-3100 in patients with pre-cancerous lesions of the vulva, or vulvar... 
From GlobeNewswire News Releases
Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma
From PR Newswire
Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA... 
From GlobeNewswire News Releases
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HIV Infection and End Lifetime of Drug Therapy
Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor 
From GlobeNewswire News Releases
George Bickerstaff Elected to Inovio’s Board of Directors
Former Novartis CFO brings finance, fundraising and M&A experience to Inovio 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth quarter and year end financial results and provide a corporate... 
From GlobeNewswire News Releases
Inovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy
SynCon WT1 and PSMA antigens join hTERT in INO-5401, Inovio’s cancer product planned for immuno-oncology combination study 
From GlobeNewswire News Releases
Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data on Inovio’s DNA-based vaccines against MERS (Middle East... 
From GlobeNewswire News Releases
Blog Coverage Inovio Inks Collaboration and License Deal with ApolloBio for Greater China
From ACCESSWIRE
Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China
Inovio to receive up to $50 million in upfront and near term payments and equity investment 
From GlobeNewswire News Releases
Research Reports Coverage on Biotech Stocks -- Inovio Pharma, Intra-Cellular Therapies, PhaseRx, and Global Blood Therapeutics
From PR Newswire
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: 
From GlobeNewswire News Releases
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.